Correlation Between Qualigen Therapeutics and Spirax Sarco

Can any of the company-specific risk be diversified away by investing in both Qualigen Therapeutics and Spirax Sarco at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Qualigen Therapeutics and Spirax Sarco into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Qualigen Therapeutics and Spirax Sarco Engineering PLC, you can compare the effects of market volatilities on Qualigen Therapeutics and Spirax Sarco and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Qualigen Therapeutics with a short position of Spirax Sarco. Check out your portfolio center. Please also check ongoing floating volatility patterns of Qualigen Therapeutics and Spirax Sarco.

Diversification Opportunities for Qualigen Therapeutics and Spirax Sarco

0.54

Correlation Coefficient

Qualigen Therapeutics  Spirax Sarco

Very weak diversification

The 3 months correlation between Qualigen and Spirax is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Qualigen Therapeutics and Spirax Sarco Engineering PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spirax Sarco Enginee and Qualigen Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Qualigen Therapeutics are associated (or correlated) with Spirax Sarco. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spirax Sarco Enginee has no effect on the direction of Qualigen Therapeutics i.e., Qualigen Therapeutics and Spirax Sarco go up and down completely randomly.

Pair Corralation between Qualigen Therapeutics and Spirax Sarco

Given the investment horizon of 90 days Qualigen Therapeutics is expected to under-perform the Spirax Sarco. In addition to that, Qualigen Therapeutics is 3.2 times more volatile than Spirax Sarco Engineering PLC. It trades about -0.11 of its total potential returns per unit of risk. Spirax Sarco Engineering PLC is currently generating about 0.0 per unit of volatility. If you would invest  4,907  in Spirax Sarco Engineering PLC on September 13, 2024 and sell it today you would lose (39.00) from holding Spirax Sarco Engineering PLC or give up 0.79% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Qualigen Therapeutics  vs.  Spirax Sarco Engineering PLC

Qualigen Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Qualigen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Spirax Sarco Enginee

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spirax Sarco Engineering PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Spirax Sarco is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Qualigen Therapeutics and Spirax Sarco

The main advantage of trading using opposite Qualigen Therapeutics and Spirax Sarco positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Qualigen Therapeutics position performs unexpectedly, Spirax Sarco can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spirax Sarco will offset losses from the drop in Spirax Sarco's long position.

The idea behind Qualigen Therapeutics and Spirax Sarco Engineering PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.